[go: up one dir, main page]

UY25247A1 - Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer - Google Patents

Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer

Info

Publication number
UY25247A1
UY25247A1 UY25247A UY25247A UY25247A1 UY 25247 A1 UY25247 A1 UY 25247A1 UY 25247 A UY25247 A UY 25247A UY 25247 A UY25247 A UY 25247A UY 25247 A1 UY25247 A1 UY 25247A1
Authority
UY
Uruguay
Prior art keywords
alzheimer
treatment
association
senile dementia
active principles
Prior art date
Application number
UY25247A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY25247A1 publication Critical patent/UY25247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY25247A 1997-11-14 1998-11-12 Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer UY25247A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
UY25247A1 true UY25247A1 (es) 2001-05-31

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25247A UY25247A1 (es) 1997-11-14 1998-11-12 Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer

Country Status (27)

Country Link
EP (1) EP1030671A1 (et)
JP (1) JP2001523642A (et)
KR (1) KR100599350B1 (et)
CN (1) CN1243540C (et)
AU (1) AU743228B2 (et)
BG (1) BG64819B1 (et)
BR (1) BR9814035A (et)
CA (1) CA2309966A1 (et)
CO (1) CO4980891A1 (et)
DZ (1) DZ2649A1 (et)
EA (1) EA003255B1 (et)
EE (1) EE04235B1 (et)
HU (1) HUP0100098A3 (et)
ID (1) ID24933A (et)
IL (2) IL136122A0 (et)
IS (1) IS5482A (et)
MY (1) MY120461A (et)
NO (1) NO20002450L (et)
NZ (1) NZ504420A (et)
OA (1) OA11464A (et)
PL (1) PL194597B1 (et)
SA (1) SA98190747B1 (et)
SK (1) SK286040B6 (et)
TR (1) TR200001262T2 (et)
TW (1) TW585766B (et)
UY (1) UY25247A1 (et)
WO (1) WO1999025363A1 (et)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0311780B8 (pt) * 2002-06-14 2021-05-25 Toyama Chemical Co Ltd composição farmacêutica para melhorar a função cerebral
DE60328198D1 (de) * 2002-08-07 2009-08-13 Novartis Ag Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
EP4023294A1 (en) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating alzheimer's disease
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
CN1126546C (zh) * 1995-03-06 2003-11-05 英特纽隆制剂药有限公司 使用胞磷胆碱减少梗塞面积
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
WO1999025363A1 (fr) 1999-05-27
JP2001523642A (ja) 2001-11-27
TW585766B (en) 2004-05-01
IL136122A0 (en) 2001-05-20
EE200000290A (et) 2001-06-15
EA200000412A1 (ru) 2000-12-25
CA2309966A1 (en) 1999-05-27
BG104428A (en) 2001-08-31
AU743228B2 (en) 2002-01-24
TR200001262T2 (tr) 2001-01-22
DZ2649A1 (fr) 2004-12-28
AU1160999A (en) 1999-06-07
NZ504420A (en) 2003-08-29
CN1243540C (zh) 2006-03-01
SK286040B6 (sk) 2008-01-07
PL340500A1 (en) 2001-02-12
KR100599350B1 (ko) 2006-07-12
MY120461A (en) 2005-10-31
HUP0100098A2 (hu) 2001-07-30
IL136122A (en) 2006-07-05
SK7112000A3 (en) 2000-10-09
IS5482A (is) 2000-05-09
EP1030671A1 (fr) 2000-08-30
OA11464A (en) 2003-11-18
HUP0100098A3 (en) 2001-12-28
CN1285742A (zh) 2001-02-28
BR9814035A (pt) 2000-09-26
BG64819B1 (bg) 2006-05-31
EE04235B1 (et) 2004-02-16
PL194597B1 (pl) 2007-06-29
KR20010032099A (ko) 2001-04-16
CO4980891A1 (es) 2000-11-27
NO20002450L (no) 2000-07-14
SA98190747B1 (ar) 2006-11-04
NO20002450D0 (no) 2000-05-11
EA003255B1 (ru) 2003-02-27
ID24933A (id) 2000-08-31

Similar Documents

Publication Publication Date Title
CO5011095A1 (es) Inhibidores de acetilcolinestarasa en combinacion con ago- nistas muscarinicos para el tratamiento de la enfermedad de alzheimer
CO4900068A1 (es) Piperazina di - n - sustituidas y piperidinas 1,4 -di- sustituidas utiles como antagonistas muscarinicos
DE60100851D1 (de) Piperidin verbindung zur behandlung von psoriasis
ATE224884T1 (de) Muscarin-antagonisten
DE60105144D1 (de) Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
AR044796A1 (es) Derivados de pirido (2, 1-a) isoquinolina como inhibidores de la dpp iv
NO20006482L (no) 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
UY24973A1 (es) Utilizacion de derivados de tetrahidropiridina para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan una desmielinizacion
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
UY25247A1 (es) Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer
ES2062425T3 (es) Piridinas, procedimientos de preparacion y medicamentos que las contienen.
ATE406353T1 (de) Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ZA987140B (en) Treatment of attention deficit disorders
DE60321452D1 (de) Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
ES2134361T3 (es) Compuestos de cromano neuroprotectores.
CA2569861A1 (en) Pyrrolidine derivatives as ccr5 antagonists
ATE344244T1 (de) Substituierte 4-phenyl-1-(1-phenyl-cyclohexyl)-1, 2,3,6-tetrahydropyridine
SI0854146T1 (en) Substituted 4-(6-fluoro-(1H)-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
HUP0001185A2 (hu) 1-Fenilalkil-1,2,3,6-tetrahidropiridinek, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
IL164018A0 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
CO4920213A1 (es) Forma en microparticulasw del clorhidrato de 1 2 2naftil etil 4 3trifluorometilfenil 1 2 3 6 tetrahidropiridina
AR040121A1 (es) Una combinacion de antagonista de nmda e inhibidores de la acetilcolina esterasa para el tratamiento de la enfermedad de alzheimer
AR016074A1 (es) Compuestos derivados de di-halo- o tri-halo-benzo [5,6] ciclohepta [1,2-b] piridinas,y una composicion farmaceutica que los comprende.
AR051845A1 (es) Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen estos compuestos, su uso y proceso para su fabricacion

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20181112